Foghorn Therapeutics (FHTX) names Danforth’s Jeff Sacher interim CFO

Rhea-AI Filing Summary

Foghorn Therapeutics Inc. announced that its Board of Directors has appointed Jeff Sacher as Treasurer and interim Chief Financial Officer, effective immediately. The company continues to search for a permanent CFO. Sacher will provide interim CFO services through Danforth Advisors, LLC, which already has a consulting agreement with the company, and Foghorn will pay Danforth an agreed hourly rate and reimburse expenses.

Sacher is a 35-year veteran of the biotechnology and investment banking industries and has served as a CFO at Danforth since May 2022. He previously worked as a senior investment banker at several firms and holds an M.B.A. from the Kellogg School of Management at Northwestern University and a B.A. in biology from Cornell University. The company states he has no family relationships with its executive officers or directors, and there are no other arrangements underlying his appointment beyond those described.

Insights

Biotech corporate governance analyst

Foghorn names an experienced interim CFO via existing advisor Danforth.

The appointment of Jeff Sacher as Treasurer and interim CFO gives Foghorn Therapeutics an experienced finance lead while it continues to search for a permanent CFO. Using Danforth Advisors, which already provides strategic and financial consulting, suggests continuity with an existing external partner rather than a full internal shake-up.

Sacher’s 35-year background in biotechnology and investment banking, plus his current CFO role at Danforth, indicates familiarity with life sciences capital markets and financial operations. His lack of family relationships with executives or directors aligns with standard independence and governance expectations.

The interim nature of the role means long-term financial leadership decisions remain open and will depend on the eventual permanent CFO hire. Subsequent company communications about the permanent appointment may provide more clarity on the stable long-term finance strategy.

false000182246200018224622025-12-032025-12-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

FORM 8-K

________________________________________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 3, 2025

________________________________________________________________________________________________

Foghorn Therapeutics Inc.

(Exact name of registrant as specified in its charter)

________________________________________________________________________________________________

Delaware

001-39634

47-5271393

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

500 Technology Square, Ste 700

Cambridge,

MA

02139

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number, including area code): (617) 586-3100

Not Applicable

(Former name or former address, if changed since last report)

________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

FHTX

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 3, 2025, the Board of Directors of Foghorn Therapeutics Inc. (the “Company”) appointed Jeff Sacher as Treasurer and interim Chief Financial Officer (“CFO”), effective immediately. The Company is continuing its search for a permanent CFO.

The Company previously entered into an agreement with Danforth Advisors, LLC (“Danforth”) pursuant to which Danforth provides strategic and financial consulting services to the Company. In addition to those services, the parties have agreed that Mr. Sacher, a CFO at Danforth, will provide interim CFO services to the Company. The Company will pay Danforth an agreed upon hourly rate for such services and will reimburse Danforth for expenses.

Mr. Sacher, age 60, is a 35-year veteran of the biotechnology and investment banking industries. He has served as a CFO at Danforth, a consultancy firm specializing in working with life sciences companies, since May 2022. Prior to his tenure at Danforth, Mr. Sacher had served as a senior investment banker for several investment banks. Mr. Sacher has an M.B.A. from the Kellogg School of Management at Northwestern University and a B.A. in biology from Cornell University. Mr. Sacher has no family relationships with any of the executive officers or directors of the Company. Other than as described herein, there are no arrangements or understandings between Mr. Sacher and any other person pursuant to which he was appointed as an officer of the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			FOGHORN THERAPEUTICS INC.
			By:						/s/ Michael J. LaCascia
									Michael J. LaCascia
									Chief Legal Officer

Date: December 4, 2025

FAQ

What did Foghorn Therapeutics (FHTX) announce in this 8-K filing?

The company reported that its Board appointed Jeff Sacher as Treasurer and interim Chief Financial Officer, effective immediately, while it continues to search for a permanent CFO.

Who is Jeff Sacher, the new interim CFO of Foghorn Therapeutics (FHTX)?

Jeff Sacher, age 60, is a 35-year veteran of the biotechnology and investment banking industries. He has served as a CFO at Danforth Advisors, LLC since May 2022 and previously worked as a senior investment banker at several firms.

How is Foghorn Therapeutics (FHTX) engaging Danforth Advisors in connection with the interim CFO role?

Foghorn has an existing agreement with Danforth Advisors, LLC for strategic and financial consulting services. Under this arrangement, Danforth’s CFO, Jeff Sacher, will provide interim CFO services, and the company will pay Danforth an agreed hourly rate and reimburse expenses.

Does Foghorn Therapeutics (FHTX) mention any conflicts or family relationships involving the interim CFO?

The company states that Mr. Sacher has no family relationships with any of its executive officers or directors, and there are no other arrangements or understandings behind his appointment beyond those described.

Is Foghorn Therapeutics (FHTX) still looking for a permanent Chief Financial Officer?

Yes. The company notes that it is continuing its search for a permanent CFO while Mr. Sacher serves in the interim role.